Vital Therapies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VTL and buy or sell other stocks, ETFs, and their options commission-free!

About VTL

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. 

CEO
Erik Lundgren, MBA
CEOErik Lundgren, MBA
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2003
Founded2003
Employees
Employees

VTL Key Statistics

Market cap
190.84M
Market cap190.84M
Price-Earnings ratio
-2.32
Price-Earnings ratio-2.32
Dividend yield
Dividend yield
Average volume
231.17K
Average volume231.17K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$15.77
52 Week high$15.77
52 Week low
$5.06
52 Week low$5.06

Stock Snapshot

The current Vital Therapies(VTL) stock price is $7.76, with a market capitalization of 190.84M. The stock trades at a price-to-earnings (P/E) ratio of -2.32.

During the trading day, Vital Therapies(VTL) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 231.17K.

The stock's 52-week range extends from a low of $5.06 to a high of $15.77.

The stock's 52-week range extends from a low of $5.06 to a high of $15.77.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.